Objective To assess the cerebral blood flow (CBF) in patients with diabetic neuropathic pain, and its changes after duloxetine therapy.
Methods Using iodine-123-N-isopropyl-p-iodoamphetamine single-photon emission computed tomography (IMP-SPECT), we performed a cross-sectional study of 44 patients with diabetes, and compared CBF in those with (n = 24) and without neuropathic pain (n = 20). In patients with neuropathic pain, we also longitudinally assessed changes in CBF 3 months after treatment with duloxetine.
Results IMP-SPECT with voxel-based analyses showed a significant increase in cerebral blood flow in the right anterior cingulate cortex and a decrease in the left ventral striatum in patients with neuropathic pain, compared with those without pain. After duloxetine treatment, volume of interest analyses revealed a decrease in cerebral blood flow in the anterior cingulate cortex in patients with significant pain relief but not in non-responders. Furthermore, voxel-based whole brain correlation analyses demonstrated that greater baseline CBF in the anterior cingulate cortex was associated with better pain relief on the numerical rating scale.
Conclusions Our results suggest that the development of neuropathic pain is associated with increased activity in the anterior cingulate cortex, and greater baseline activation of this region may predict treatment responsiveness to pharmacological intervention.
Trial registration number UMIN000017130;Results.
- cerebral blood flow
- diabetic neuropathy
Statistics from Altmetric.com
Contributors KW and SM designed the study. SI, SO, KS, YS, MB, HA, TaS, ToS, KY and MT collected clinical and electrophysiological data. KM and TI collected IMP-SPECT and MRI data. KK and HM analysed MRI images. SH analysed and interpreted the data. KN supervised statistical analyses. KW and SH drafted the manuscript. SM, TS, TU supervised this study.
Funding This study is funded by Shionogi & Co., Ltd and by a Research Grant from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (SM, Kakenhi- 25461308: SK, Kakenhi- 26461305). The sponsors played no role in the design and management of the study, collection and analysis of data, interpretation of the results or the writing of the writing of the report.
Competing interests SM received lecture and consultation fee from Shionogi & Co., Ltd and Pfizer Inc. SK serves as a Deputy Editor of “Journal of Neurology, Neurosurgery, and Psychiatry” and Editorial Board member of the “Journal of the Neurological Sciences”.
Patient consent Obtained.
Ethics approval The Institutional Review Board and Ethical Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.